<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004515.pub2" GROUP_ID="DEPRESSN" ID="061602110918122764" MERGED_FROM="" MODIFIED="2008-11-06 04:18:33 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;/p&gt;&lt;p&gt;Old title: Valerian for anxiety disorder&lt;/p&gt;" NOTES_MODIFIED="2008-11-06 03:15:14 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="113" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-11-06 04:18:33 +0100" MODIFIED_BY="Rachel Churchill">
<TITLE>Valerian for anxiety disorders</TITLE>
<CONTACT MODIFIED="2008-11-06 04:18:33 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="13191" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lincoln Sakiara</FIRST_NAME><LAST_NAME>Miyasaka</LAST_NAME><POSITION>Reviewer</POSITION><EMAIL_1>lincoln.miyasaka@terra.com.br</EMAIL_1><URL>www.centrocochranedobrasil.org</URL><ADDRESS><ORGANISATION>Brazilian Cochrane Centre</ORGANISATION><ADDRESS_1>Universidade Federal de São Paulo</ADDRESS_1><ADDRESS_2>Rua de Pedro Toledo 598, Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-06 04:18:33 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="13191" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lincoln Sakiara</FIRST_NAME><LAST_NAME>Miyasaka</LAST_NAME><POSITION>Reviewer</POSITION><EMAIL_1>lincoln.miyasaka@terra.com.br</EMAIL_1><URL>www.centrocochranedobrasil.org</URL><ADDRESS><ORGANISATION>Brazilian Cochrane Centre</ORGANISATION><ADDRESS_1>Universidade Federal de São Paulo</ADDRESS_1><ADDRESS_2>Rua de Pedro Toledo 598, Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON><PERSON ID="5183" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Álvaro</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Atallah</LAST_NAME><SUFFIX>MD, PhD.</SUFFIX><POSITION>Professor of Emergency Medicine and Evidence-Based Medicine, Director of Brazilian Cochrane Centre</POSITION><EMAIL_1>atallahmbe@uol.com.br</EMAIL_1><EMAIL_2>cochrane.dmed@epm.br</EMAIL_2><MOBILE_PHONE>+55 11 8173 0404</MOBILE_PHONE><ADDRESS><DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Universidade Federal de  São Paulo / Escola Paulista de Medicina</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo 598 </ADDRESS_1><ADDRESS_2>Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>CEP 04039-001</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><PHONE_2>+55 11 5571 4721</PHONE_2><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON><PERSON ID="9639" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo </FIRST_NAME><LAST_NAME>Soares</LAST_NAME><POSITION>Honorary Fellow</POSITION><EMAIL_1>bgos@terra.com.br</EMAIL_1><ADDRESS><ORGANISATION>Brazilian Cochrane Centre</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo 598</ADDRESS_1><ADDRESS_2>Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-06 04:18:33 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Minor update: 13/07/06&lt;/p&gt;&lt;p&gt;New studies sought but none found: 04/08/06&lt;/p&gt;" NOTES_MODIFIED="2008-11-06 03:14:35 +0000" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="21" MONTH="8" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="8" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="6" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="21" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Brazilian Cochrane Centre</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-06 03:15:14 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Valerian for anxiety disorders</TITLE>
<SUMMARY_BODY>
<P>Anxiety disorders are a very common mental health problem in the community. Most of the medications used to treat anxiety have side effects. Valerian is a phytotherapeutic medication frequently used for insomnia. The aim of this study was to investigate the efficacy and safety of valerian for anxiety disorders. Only one study was identified, involving 36 patients and comparing valerian with placebo and diazepam. This study found no significant differences in effectiveness between valerian and placebo, or between valerian and diazepam, for clinician-rated anxiety symptoms, and that both valerian and diazepam were equally well tolerated by patients. However, additional studies with larger numbers of patients are necessary before drawing conclusions about the effectiveness and safety of valerian as a treatment option for anxiety disorders.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-06 03:15:14 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-11-06 03:15:03 +0000" MODIFIED_BY="[Empty name]">
<P>Anxiety disorders are very common mental health problems in the general population and in primary care settings. Herbal medicines are popular and used worldwide and might be considered as a treatment option for anxiety if shown to be effective and safe.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To investigate the effectiveness and safety of valerian for treating anxiety disorders.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Electronic searches: The Cochrane Collaboration Depression, Anxiety and Neurosis Cochrane Controlled Trials Register (CCDANCTR-Studies and CCDANCTR-References) searched on 04/08/2006, MEDLINE, Lilacs. References of all identified studies were inspected for additional studies. First authors of each included study, manufacturers of valerian products, and experts in the field were contacted for information regarding unpublished trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials (RCTs) and quasi-randomised trials of valerian extract of any dose, regime, or method of administration, for people with any primary diagnosis of general anxiety disorder, anxiety neurosis, chronic anxiety status, or any other disorder in which anxiety is the primary symptom (panic disorder, obsessive compulsive disorder, social phobia, agoraphobia, other types of phobia, postraumatic stress disorder). Effectiveness was measured using clinical outcome measures and other scales for anxiety symptoms.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-11-06 03:15:03 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently applied inclusion criteria, extracted and entered data, and performed the trial quality assessments. Where disagreements occurred, the third review author was consulted. Methodological quality of included trials was assessed using Cochrane Handbook criteria. For dichotomous outcomes, relative risk (RR) was calculated, and for continuous outcomes, the weighted mean difference (WMD) was calculated, with their respective 95% confidence intervals.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-06 03:15:14 +0000" MODIFIED_BY="[Empty name]">
<P>One RCT involving 36 patients with generalised anxiety disorder was eligible for inclusion. This was a 4 week pilot study of valerian, diazepam and placebo. There were no significant differences between the valerian and placebo groups in HAM-A total scores, or in somatic and psychic factor scores. Similarly, there were no significant differences in HAM-A scores between the valerian and diazepam groups, although based on STAI-Trait scores, significantly greater symptom improvement was indicated in the diazepam group. There were no significant differences between the three groups in the number of patients reporting side effects or in dropout rates.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Since only one small study is currently available, there is insufficient evidence to draw any conclusions about the efficacy or safety of valerian compared with placebo or diazepam for anxiety disorders. RCTs involving larger samples and comparing valerian with placebo or other interventions used to treat of anxiety disorders, such as antidepressants, are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Anxiety disorders are a very common mental health problem in the general population and in the primary care setting. In the US National Comorbidity Survey <LINK REF="REF-Kessler-1994" TYPE="REFERENCE">Kessler 1994</LINK> found a one year prevalence for anxiety disorders of 17% and a lifetime prevalence of almost 25%. Using the Composite International Diagnostic Interview (CIDI) in 1996-99, <LINK REF="REF-Bijl-1998" TYPE="REFERENCE">Bijl 1998</LINK> included 7076 people in 90 municipalities in the Netherlands, and detected a prevalence rate for anxiety of 19.3% in the general population. In Brazil, the prevalence of anxiety was reported at 12.1% in Brasilia, 6.9% in São Paulo and 5.4% in Porto Alegre (<LINK REF="REF-Almeida_x002d_Filho-1997" TYPE="REFERENCE">Almeida-Filho 1997</LINK>). One study has found a marked reduction in quality of life and psychosocial functioning in people with anxiety disorders (<LINK REF="REF-Mendlowicz-2000" TYPE="REFERENCE">Mendlowicz 2000</LINK>).</P>
<P>Although anxiety is a treatable disorder, it is often not diagnosed and treated properly. The majority of patients suffering from anxiety consult their general practitioner, and often their complaint presents as a physical symptom, such as headache, palpitations, breathing difficulties or chest pain (<LINK REF="REF-Walley-1994" TYPE="REFERENCE">Walley 1994</LINK>). Anxiety may be associated with physical disorders such as diabetes, arthritis and cancer, or it may be the primary symptom of a specific psychiatric disorder such as generalized anxiety disorder, post-traumatic stress disorder, panic or obsessive compulsive disorder. </P>
<P>Benzodiazepines are effective in short -term treatment but their overuse may cause dependence (<LINK REF="REF-Priest-1988" TYPE="REFERENCE">Priest 1988</LINK>). Psychotherapy is effective and is commonly used to treat anxiety (<LINK REF="REF-Borkovec-1987" TYPE="REFERENCE">Borkovec 1987</LINK>; <LINK REF="REF-Borkovec-1993" TYPE="REFERENCE">Borkovec 1993</LINK>; <LINK REF="REF-Taylor-1978" TYPE="REFERENCE">Taylor 1978</LINK>; <LINK REF="REF-Taylor-1988" TYPE="REFERENCE">Taylor 1988</LINK>). A systematic review on psychological therapies for generalised anxiety disorder has been conducted and is expected to be published soon in The Cochrane Library (<LINK REF="REF-Hunot-2006" TYPE="REFERENCE">Hunot 2006</LINK>). Another systematic review has found that cognitive behavioural therapies and pharmacological treatments including buspirone, trazodone, imipramine and ritanserin significantly improved anxiety (<LINK REF="REF-Gould-1997" TYPE="REFERENCE">Gould 1997</LINK>). However, psychotherapy may be an unrealistic option in public health settings in many countries as it is costly and time consuming, and although pharmacological treatments are effective, they may be limited by their side effects and cost. Herbal medicines are in popular usage worldwide, and could be considered as a treatment option for anxiety disorders if shown to be effective and secure. A systematic review on the effectiveness of kava kava showed its superiority as compared with placebo (<LINK REF="REF-Pittler-2002" TYPE="REFERENCE">Pittler 2002</LINK>). No systematic review on valerian for anxiety has yet been conducted. </P>
<P>Valerian is one of the most popularly used herbal medicines for insomnia (<LINK REF="REF-Donath-2000" TYPE="REFERENCE">Donath 2000</LINK>) and is also used for anxiety. It is used in the form of a dried herb (0.5-2.0g taken 3-4 times a day), extract (0.5-2.0 ml) or tincture (2-4 ml) (<LINK REF="REF-BHMA-1992" TYPE="REFERENCE">BHMA 1992</LINK>). Hydroalcoholic and aqueous extracts of valerian roots have shown affinity for the GABA-A receptor in the brains of rats (<LINK REF="REF-Mennini-1993" TYPE="REFERENCE">Mennini 1993</LINK>). In another experiment, valerian oil injected intraperitoneally showed central depressive and muscle relaxation activity in mice (<LINK REF="REF-Hendriks-1981" TYPE="REFERENCE">Hendriks 1981</LINK>). Valepotriates are the most active principle of valerian, but are very labile and unlikely to be present in the finished preparations. In rats there is evidence of inhibition of motor activity, inhibition of aggressivity, prolongation of anaesthesia by hexobarbital (<LINK REF="REF-Petkov-1974" TYPE="REFERENCE">Petkov 1974</LINK>), but with better motor coordination (<LINK REF="REF-Von-Eickstedt-1969" TYPE="REFERENCE">Von Eickstedt 1969</LINK>). In humans, valerian does not seem to potentiate the effect of alcohol, but demonstrates a positive action in tests of concentration and efficiency (<LINK REF="REF-Mayer-1974" TYPE="REFERENCE">Mayer 1974</LINK>), and has been successful in the treatment of insomnia and tension (<LINK REF="REF-Schmidt_x002d_Voigt-1986" TYPE="REFERENCE">Schmidt-Voigt 1986</LINK>, <LINK REF="REF-Vorbach-1996" TYPE="REFERENCE">Vorbach 1996</LINK>, <LINK REF="REF-Leathwood-1985" TYPE="REFERENCE">Leathwood 1985</LINK>, <LINK REF="REF-Donath-2000" TYPE="REFERENCE">Donath 2000</LINK>; <LINK REF="REF-Stevinson-2000" TYPE="REFERENCE">Stevinson 2000</LINK>; <LINK REF="REF-Ziegler-2002" TYPE="REFERENCE">Ziegler 2002</LINK>). Although valerian has been used for a long time for treating anxiety disorders its efficacy and side effects are not yet fully established. This review aimed to examine the effectiveness and safety of anxiety disorders. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To investigate the effectiveness and safety of valerian for treating anxiety disorders. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised and quasi-randomised controlled trials. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People aged 16 and over, with a primary diagnosis of anxiety disorders or anxiety neurosis or chronic anxiety status, or any other disorder in which anxiety was the primary symptom (generalised anxiety disorder, panic disorder, obsessive compulsive disorder, social phobia, agoraphobia, other types of phobia, post-traumatic stress disorder), according to DSM-III or DSM-IV diagnostic criteria (<LINK REF="REF-APA-1987" TYPE="REFERENCE">APA 1987</LINK>, <LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>), irrespective of gender and ethnic background. </P>
<P>Studies in which anxiety was a secondary symptom of a different disorder (for example, depression or any other psychiatric diagnoses) were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Valerian (also called valepotriates or valerian extract), any dose, regime, or method of administration. Trials where valerian was used in combination with another drug were not included.</P>
<P>Control: placebo, other drugs, psychotherapy, or no intervention.</P>
<P>Planned comparisons:<BR/>(i) valerian versus placebo<BR/>(ii) valerian versus other drugs<BR/>(iii) valerian versus psychotherapy<BR/>(iv) valerian versus no intervention<BR/>
</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>
<B>Primary outcome</B>
<BR/>Effectiveness, measured using clinical outcome measures such as Hamilton Anxiety Scale (HAM-A) (<LINK REF="REF-Hamilton-1959" TYPE="REFERENCE">Hamilton 1959</LINK>) and other scales for anxiety symptoms:<BR/>(a) improvement in anxiety (continuous outcome)<BR/>(b) absence of treatment response (dichotomous outcome)</P>
<P>
<B>Secondary outcomes</B>
<BR/>(a) Acceptability of treatment :<BR/>- number of participants reporting side effects<BR/>- number of participants dropping out due to side effects<BR/>(b) Side effects<BR/>(c) Total number of drop-outs<BR/>(d) Suicide attempts<BR/>(e) Use/misuse of substances<BR/>(f) Use of health services<BR/>(g) Death<BR/>(h) Quality of life</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>
<B>Electronic databases</B>
<BR/>The Cochrane Collaboration Depression, Anxiety and Neurosis Cochrane Controlled Trials Register was searched using the following strategy </P>
<P>CCDANCTR-Studies - searched on 04/08/2006<BR/>Intervention = valerian</P>
<P>CCDANCTR-References - searched on 04/08/2006<BR/>Freetext = valerian* OR valepotriate.</P>
<P>Lilacs (2005) and MEDLINE (2005) were searched using standard phrases for 'controlled trials' and for 'anxiety disorders' associated to 'valerian OR valepotriate'. </P>
<P>There were no restrictions related to language or date of publication of the studies.</P>
<P>
<B>Handsearches</B>
<BR/>The references of all identified studies were inspected for additional studies. </P>
<P>
<B>Personal communication</B>
<BR/>The first author of each included study was contacted for information regarding unpublished trials and additional data when necessary. The manufacturers of valerian products in Brazil and experts in the field were also contacted for information regarding unpublished trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Selection of trials</B>
<BR/>Two review authors (LSM and BGOS) independently selected the trials found through the search strategy, extracted the data, assessed trial quality, and analysed results. Where any disagreements occurred, the third review author (ANA) was consulted, and if consensus was not yet reached, data were not included in the review until the author of the trial was able to provide clarification on the question posed.</P>
<P>
<B>Data extraction</B>
<BR/>Review authors screened the abstracts of all publications obtained by the search strategy and considered eligible in fulfilling the inclusion criteria. Data concerning participant characteristics, intervention details and outcome measures from the included studies were extracted independently using a standard extraction form with the following items:<BR/>(a) General information: published or not, title, authors, contact address, country, resource, publication idiom, publication year, duplication of publishing, sponsor.<BR/>(b) Characteristics of the study: design, length, whether randomised and method, allocation procedure, blinding (patients, administrator care and outcome appraiser), allocation check.<BR/>(c) Intervention: placebo inclusion, intervention and controls (dose, route of administration and duration).<BR/>(d) Patients: inclusion and exclusion criteria, total number of randomised and analysed subjects, sex, age, basic characteristics, diagnostic criteria, length of disease and similarity of groups on the basic characteristics (including any co-morbidity), assessment on complications, sub-groups.<BR/>(e) Outcomes: Those specified in the section on 'Types of outcomes', any other outcome assessed, other events, extension of attendance, and quality of related outcomes.<BR/>(f) Results: outcomes and evaluation time (including the evaluative measure), where necessary converted to the measurement of the effects specified below; intention to treat analysis.</P>
<P>
<B>Quality assessment</B>
<BR/>Methodological quality of the trials included in this review was assessed using the criteria described in the Cochrane Handbook (<LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>). The Cochrane Handbook criteria are based on the evidence of a strong relationship between allocation concealment and potential for bias in the results (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). The categories for these criteria are as follows: <BR/>A - Low risk of bias (adequate allocation concealment) <BR/>B - Moderate risk of bias (unclear allocation concealment) <BR/>C - High risk of bias (inadequate allocation concealment)</P>
<P>For the purpose of analyses in this review, trials were included if they met criteria A or B. Additionally, a cut-off of two points on the Jadad scale was used to check the assessment made by the Handbook criteria (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). However, the Jadad scale was not used to exclude trials in this review.</P>
<P>
<B>Measures of treatment effect</B>
</P>
<P>
<B>Dichotomous outcomes</B>
<BR/>Dichotomous outcomes were reported for each included trial by calculating relative risks (RR) with the uncertainty in each result being expressed through 95% confidence intervals (CI), using the fixed effect model. When further studies become available, dichotomous data from individual trials will be combined in a meta-analysis, with the estimates of RR based on the random effects model, as it takes into account any between study differences, even if there is no statistically significant heterogeneity, and gives the same result as the fixed effects model when there is no between study variance. Where overall results are significant, the number needed to treat (NNT) or number needed to harm (NNH) to produce one outcome will be calculated.</P>
<P>
<B>Continuous outcomes</B>
<BR/>Continuous outcomes were reported for each included trial according to the difference between groups in the mean treatment effect and its standard deviation, using the fixed effect model. When multiple outcome measures were described in a single study, for the purposes of pooling results, a single 'best available' outcome measure was chosen according to the authors' specification as the principal outcome or what was reported first. When further studies become available, continuous outcomes in individual studies will be combined by calculating the weighted mean difference (WMD) (where the same scale is used to measure an outcome in a comparison) or the standardised mean difference (SMD) (where different scales are used to measure the same outcome in a comparison), together with 95%CIs.</P>
<P>Information on missing data was clarified through contact with the authors.</P>
<P>
<B>Methods for future updates of the review </B>
<BR/>The following methods will be used when further studies are included in the review:</P>
<P>
<B>Assessment of heterogeneity</B>
<BR/>Heterogeneity in the results of trials will be assessed both by inspection of graphical presentations and by calculating a formal Chi-square test of heterogeneity, with heterogeneity assumed to be present when the significance level is smaller than 0.10 (p &lt; 0.10). </P>
<P>
<B>Subgroup analysis and investigation of heterogeneity</B>
<BR/>Where significant heterogeneity is present, an attempt will be made to explain the differences based on the clinical characteristics of the included studies. Potential sources of heterogeneity may be sample differences, diagnostic criteria or differences in medication dosage. <BR/>
<B>
<BR/>Sensitivity analysis</B>
<BR/>Sensitivity analysis will be performed excluding quasi-randomised studies. </P>
<P>
<B>Assessment of reporting bias</B>
<BR/>A funnel plot will be produced to investigate the possibility of publication bias. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>
<B>Results of the search<BR/>
</B>The electronic searches identified one reference in Lilacs, two references in MEDLINE, and five references in CCDANCTR-Studies. Of the eight studies identified, only one was eligible for inclusion in the review (<LINK REF="STD-Andreatini-2002" TYPE="STUDY">Andreatini 2002</LINK>). </P>
<P>Manufacturers of valerian in Brazil (Nikkho, Solnay Farma, Barrenne, Fontovit, Pharmaton/Boehringer Ingelhein, Catarinense) were contacted asking for unpublished trials, but no further studies were found.</P>
<P>
<B>Included studies</B>
<BR/>The study by <LINK REF="STD-Andreatini-2002" TYPE="STUDY">Andreatini 2002</LINK> was a pilot study, using a randomised controlled design, which compared valepotriates (valerian) with diazepam and placebo. The trial duration was four weeks. The sample consisted of 36 participants with a diagnosis of generalised anxiety disorder, according to DSM-III criteria. The mean age of the sample was 41 years, and 21 of the participants were female. The majority of participants presented with secondary disorders. </P>
<P>
<LINK REF="STD-Andreatini-2002" TYPE="STUDY">Andreatini 2002</LINK> used a clinician-rated scale, the HAM-A, and a self-report scale, the STAI-Trait, to measure anxiety symptoms. HAM-A scores were reported for the overall total score, together with a psychic factor (including anxious mood, tension, fears, concentration disturbances) and somatic factor (including insomnia, respiratory and cardiovascular symptoms).</P>
<P>
<B>Excluded studies<BR/>
</B>Seven studies were excluded from the review (see also Table of excluded studies). </P>
<P>The study by <LINK REF="STD-Delsignore-1992" TYPE="STUDY">Delsignore 1992</LINK> was excluded from the review because the results were poorly presented, and could not be re-analysed (SDs were not presented for continuous outcomes). Similarly, the study by <LINK REF="STD-Rabezzana-1995" TYPE="STUDY">Rabezzana 1995</LINK> was excluded because SDs were not shown for continuous outcomes. It has not yet been possible to contact the authors for further information. </P>
<P>The study by <LINK REF="STD-Maisenbacher-1992" TYPE="STUDY">Maisenbacher 1992</LINK> was excluded because it did not use an RCT design. <LINK REF="STD-McCutcheon-1996" TYPE="STUDY">McCutcheon 1996</LINK> was excluded because nine phytotherapeutic preparations were used. The study by <LINK REF="STD-Panijel-1985" TYPE="STUDY">Panijel 1985</LINK> was excluded because valerian was combined with hypericum for comparison with diazepam. The study by <LINK REF="STD-Bourin-1997" TYPE="STUDY">Bourin 1997</LINK> was excluded because it used a combination of six extracts. Finally, <LINK REF="STD-Cerny-1998" TYPE="STUDY">Cerny 1998</LINK> was excluded because healthy volunteers were used. </P>
<P>
<B>Awaiting assessment</B>
<BR/>There are no studies currently awaiting assessment.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<B>Allocation</B>
<BR/>The study by <LINK REF="STD-Andreatini-2002" TYPE="STUDY">Andreatini 2002</LINK> carried out the randomisation procedure using a computer program. Whether the allocation was concealed or not was unclear, therefore it was classified as B, in accordance with Cochrane Handbook criteria.</P>
<P>
<B>Blindness<BR/>
</B>The study by <LINK REF="STD-Andreatini-2002" TYPE="STUDY">Andreatini 2002</LINK> was a double blind RCT. Maintenance of the double-blind procedure was tested for patients and researchers. </P>
<P>
<B>Dropouts<BR/>
</B>The overall dropout rate for <LINK REF="STD-Andreatini-2002" TYPE="STUDY">Andreatini 2002</LINK> was 14%, with two dropouts reported for valepotriates (valerian), two for placebo and one for diazepam. Missing data for dropouts was managed through use of last observation carried forward (LOCF).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>As described above, only one study was included in the review (<LINK REF="STD-Andreatini-2002" TYPE="STUDY">Andreatini 2002</LINK>), a double-blind randomised controlled trial comparing valepotriates (valerian) with diazepam and placebo. </P>
<P>
<B>1. VALERIAN vs PLACEBO<BR/>
</B>
<BR/>
<B>Effectiveness</B>
<BR/>Based on the HAM-A scale overall score at post-treatment, no significant difference in symptom reduction was noted between valerian and placebo (WMD -1.40, 95%CI -7.93 to 5.13). Similarly, no significant differences in symptom reduction were noted between valerian and placebo for the HAM-A somatic factor (WMD 0.40, 95% CI -3.12 to 3.92), for the HAM-A psychic factor (WMD -1.80, 95% CI -6.22 to 2.62) or for STAI-Trait mean scores (WMD 0.70, 95% CI -9.93, 11.33). </P>
<P>
<B>Side effects</B>
<BR/>No side effects were reported by any patients in the valerian group, and were reported by one person in the placebo group. The patient's complaint was somnolence.</P>
<P>
<B>Dropout</B>
<BR/>There was no significant difference in dropout rate between valerian and placebo groups.</P>
<P>
<B>2. VALERIAN vs DIAZEPAM</B>
</P>
<P>
<B>Effectiveness</B>
<BR/>Based on the HAM-A scale total score at post-treatment, no significant difference in symptom reduction was noted between valerian and diazepam (WMD 0.40, 95% CI -6.22 to 7.02). Similarly, no significant differences in symptom reduction were noted between valerian and diazepam for the HAM-A somatic factor (WMD -0.20, 95% CI -2.93 to 2.53) or for the HAM-A psychic factor (WMD 0.60, 95% CI -3.82 to 5.02). The diazepam group had significantly lower STAI-Trait mean scores at post-treatment than the valerian group (WMD 11.40, 95% CI 1.90, 20.90).</P>
<P>
<B>Side effects</B>
<BR/>No side effects were reported by patients in the valerian group, and were reported by one person in the diazepam group. The patient's complaint was somnolence.</P>
<P>
<B>Dropout</B>
<BR/>There was no significant difference in dropout rate between the valerian and diazepam groups.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Only one small pilot study with 36 patients was eligible for inclusion in this review (<LINK REF="STD-Andreatini-2002" TYPE="STUDY">Andreatini 2002</LINK>). This study compared the efficacy of valerian with placebo and with diazepam, and each group consisted of 12 patients. The reduction in clinician-rated anxiety symptoms at post-treatment, based on the HAM-A scale, was similar for the three groups. Diazepam appeared to be superior to valerian in reducing self-report anxiety symptoms, based on the STAI-Trait scale. Side effect profiles were similar for valerian and diazepam. </P>
<P>In view of the lack of available data, on the basis of the current evidence, it is unclear whether or not valerian is effective and safe when compared with placebo, or when compared with diazepam, in the treatment of anxiety disorders. Further efforts will be made to obtain missing data from studies that are currently unable to contribute to the review (<LINK REF="STD-Delsignore-1992" TYPE="STUDY">Delsignore 1992</LINK>, <LINK REF="STD-Rabezzana-1995" TYPE="STUDY">Rabezzana 1995</LINK>). <BR/> </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Since only one study is included in this review, there is insufficient evidence to draw any conclusions on the efficacy or safety of valerian in comparison to placebo or diazepam for anxiety disorders. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Randomised controlled trials are needed involving larger samples and comparing valerian to placebo and other available interventions, such as antidepressants, for the treatment of anxiety disorders.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The staff of the Brazilian Cochrane Centre for their interest in solving daily doubts, and facilitating access to Cochrane data.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>LSM - protocol writing, searching, trial selection, data extraction, completion of review.</P>
<P>ANA - protocol writing, expertise advice, completion of review.</P>
<P>BGOS - protocol writing, searching, trial selection, data extraction, completion of review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Andreatini-2002" NAME="Andreatini 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andreatini R, Sartori VA, Seabra MLV, Leite JR</AU>
<TI>Effect of valepotriates (valerian extract) in Generalised Anxiety Disorder: a randomised placebo-controlled pilot study</TI>
<SO>Phytotherapy Research</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>650-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bourin-1997" NAME="Bourin 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourin M, Bougerol T, Guitton B, Broutin E</AU>
<TI>A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo</TI>
<SO>Fundamental and Clinical Pharmacology</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>2</NO>
<PG>127-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cerny-1998" NAME="Cerny 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cerny A, Schmid K</AU>
<TI>Tolerability and efficacy of valerian/lemon balm in healthy volunteers ( a double-blind placebo controlled multicentre study)</TI>
<SO>Fitoterapia</SO>
<YR>1999</YR>
<VL>70</VL>
<PG>221-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delsignore-1992" NAME="Delsignore 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Delsignore R, Orlando S, Costi D, Baroni MC, Butturini U</AU>
<TI>Clinical comparative evaluation of a stabilized valeriana extract and placebo</TI>
<TO>Avaliação clinica comparativa com placebo de um extrato estabilizado de valeriana</TO>
<SO>A Folha Medica</SO>
<YR>1992</YR>
<VL>104</VL>
<NO>5</NO>
<PG>191-196</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maisenbacher-1992" NAME="Maisenbacher 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maisenbacher J, Podzuweit H</AU>
<TI>Valerian and Melissa - Mild Psychopharmaceuticals</TI>
<SO>Therapiewoche</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>37</NO>
<PG>2140-2144</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCutcheon-1996" NAME="McCutcheon 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McCutcheon LE</AU>
<TI>Treatment of anxiety with a homeopathic remedy</TI>
<SO>Journal of Applied Nutrition</SO>
<YR>1996</YR>
<VL>48</VL>
<NO>1,2</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panijel-1985" NAME="Panijel 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panijel M</AU>
<TI>Treatment of moderately severe anxiety states</TI>
<SO>Therapiewoche</SO>
<YR>1985</YR>
<VL>41</VL>
<PG>4659-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabezzana-1995" NAME="Rabezzana 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rabezzana G</AU>
<TI>Tratamento dei disturbi d'ansia de grado lieve e medio con prodotti a base naturale: valutazione dell"efficacia e tollerabilità del Sedatol</TI>
<SO>Riv It Biol Med</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>126-133</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Almeida_x002d_Filho-1997" NAME="Almeida-Filho 1997" TYPE="JOURNAL_ARTICLE">
<AU>Almeida-Filho N, Mari JJ, Coutinho E, Franca JF, Fernandes J, Andreoli SB et al</AU>
<TI>Brazilian multicentric study of psychiatric morbidity: Methodological features and prevalence estimates</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>171</VL>
<PG>524-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1987" NAME="APA 1987" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and statistical manual of mental disorders (DSM-III-R)</SO>
<YR>1987</YR>
<EN>3rd revised</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BHMA-1992" NAME="BHMA 1992" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" TYPE="BOOK">
<AU>British Herbal Medicine Association</AU>
<SO>British Herbal Compendium Vol. 1</SO>
<YR>1992</YR>
<PB>British Herbal Medicine Association</PB>
<CY>Bournemouth</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bijl-1998" NAME="Bijl 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bijl RV, Ravelli A, van Zessen G</AU>
<TI>Prevalence of psychiatric disorder in the general population: Results of the Netherland Mental Health Survey and Incidence Study (NEMESIS)</TI>
<SO>Social Psychiatry &amp; Psychiatric Epidemiology</SO>
<YR>1998</YR>
<VL>33</VL>
<NO>12</NO>
<PG>587-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borkovec-1987" NAME="Borkovec 1987" TYPE="JOURNAL_ARTICLE">
<AU>Borkovec TD, Mathews AM, Chambers AM, Ebrahimi S, Lytle R, Nelson R et al</AU>
<TI>The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety disorder</TI>
<SO>Journal of Consulting &amp; Clinical Psychology</SO>
<YR>1987</YR>
<VL>55</VL>
<NO>6</NO>
<PG>883-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borkovec-1993" NAME="Borkovec 1993" TYPE="JOURNAL_ARTICLE">
<AU>Borkovec TD, Costello E</AU>
<TI>Efficacy of applied relaxation and cognitive behavioral therapy in the treatment of generalized anxiety disorder</TI>
<SO>Journal of Consulting &amp; Clinical Psychology</SO>
<YR>1993</YR>
<VL>61</VL>
<NO>4</NO>
<PG>611-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" NAME="Clarke 2000" TYPE="BOOK">
<AU>Clarke M, Oxman AD</AU>
<SO>Cochrane Collaboration Handbook</SO>
<YR>2000</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donath-2000" NAME="Donath 2000" TYPE="JOURNAL_ARTICLE">
<AU>Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I</AU>
<TI>Critical evaluation of the effect of valerian extract on sleep structure and sleep quality</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2000</YR>
<VL>33</VL>
<NO>2</NO>
<PG>47-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gould-1997" NAME="Gould 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gould RA, Otto MW, Pollack MH, Yap L</AU>
<TI>Cognitive behavioural and pharmacological treatment of generalized anxiety disorders: Preliminary meta-analysis</TI>
<SO>Behavior Therapy</SO>
<YR>1997</YR>
<VL>28</VL>
<NO>2</NO>
<PG>285-305</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1959" NAME="Hamilton 1959" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>The assessment of anxiety states by rating</TI>
<SO>British Journal of Medical Psychology</SO>
<YR>1959</YR>
<VL>32</VL>
<PG>50-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hendriks-1981" NAME="Hendriks 1981" TYPE="JOURNAL_ARTICLE">
<AU>Hendriks H, Bos R, Allersma DP, Malingre TM, Koster AS</AU>
<TI>Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis</TI>
<SO>Planta Medica</SO>
<YR>1981</YR>
<VL>42</VL>
<NO>1</NO>
<PG>62-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunot-2006" NAME="Hunot 2006" TYPE="COCHRANE_REVIEW">
<AU>Hunot V, Churchill R, Silva de Lima M, Teixeira V</AU>
<TI>Psychological therapies for generalised anxiety disorder</TI>
<TO>Psychotherapies for generalized anxiety disorder</TO>
<SO>Cochrane Library</SO>
<YR>2006</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kessler-1994" NAME="Kessler 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al</AU>
<TI>Lifetime and 12 month prevalence of DSM III-R psychiatric disorders in United States</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>1</NO>
<PG>8-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leathwood-1985" NAME="Leathwood 1985" TYPE="JOURNAL_ARTICLE">
<AU>Leathwood PD, Chauffard F</AU>
<TI>Aqueous extract of valerian reduces latency to fall asleep in man</TI>
<SO>Planta Medica</SO>
<YR>1985</YR>
<VL>51</VL>
<NO>2</NO>
<PG>144-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayer-1974" NAME="Mayer 1974" TYPE="JOURNAL_ARTICLE">
<AU>Mayer B, Springer E</AU>
<TI>Psychoexperimental studies on the effect of a valepotriate combination as well as the combined effects of valtratum and alcohol</TI>
<TO>Psyschoexperimentelle untersuchungen zur wirking einer Valepotriatkombination sowie zur Kombinierten wirkung von Valtratum und Alkohol</TO>
<SO>Arzneimittel-Forschung</SO>
<YR>1974</YR>
<VL>24</VL>
<NO>12</NO>
<PG>2066-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mendlowicz-2000" NAME="Mendlowicz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mendlowicz MV, Stein MB</AU>
<TI>Quality of life in individuals with anxiety disorders</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<NO>6</NO>
<PG>669-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mennini-1993" NAME="Mennini 1993" TYPE="JOURNAL_ARTICLE">
<AU>Mennini T, Bernasconi P, Bombardelli E, Morazzoni P</AU>
<TI>In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in rat brain</TI>
<SO>Fitoterapia</SO>
<YR>1993</YR>
<VL>64</VL>
<NO>4</NO>
<PG>291-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petkov-1974" NAME="Petkov 1974" TYPE="JOURNAL_ARTICLE">
<AU>Petkov VD, Manolov PN, Marekov NL, Popov SS, Handjieva NB</AU>
<TI>Pharmacological studies on a mixture of valepotrietes isolated from Valeriana officinalis</TI>
<SO>Doklady Bolgarskoi Akademii Nauk</SO>
<YR>1974</YR>
<VL>27</VL>
<PG>1007-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pittler-2002" NAME="Pittler 2002" TYPE="COCHRANE_REVIEW">
<AU>Pittler MH, Ernst E</AU>
<TI>Kava extract for treating anxiety</TI>
<SO>Cochrane Library</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Priest-1988" NAME="Priest 1988" TYPE="JOURNAL_ARTICLE">
<AU>Priest RG, Montgomery SA, Priest RG, Montgomery SA</AU>
<TI>Benzodiazepines and dependance: a college statement</TI>
<SO>Bulletin of the Royal College of Psychiatrists</SO>
<YR>1988</YR>
<VL>12</VL>
<PG>107-08</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmidt_x002d_Voigt-1986" NAME="Schmidt-Voigt 1986" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt-Voigt J</AU>
<TI>Treatment of nervous sleep disorders and unrest with a sedative of purely vegetable origin</TI>
<TO>Die Behandlung nervoser schfstorungen und innerer unruhe mit einem rein pflanzlichen sedativum</TO>
<SO>Therapiewoche</SO>
<YR>1986</YR>
<VL>36</VL>
<NO>7</NO>
<PG>663-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Haves RJ, Altman DG</AU>
<TI>Empirical evidence of bias: Dimension of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stevinson-2000" NAME="Stevinson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Stevinson C, Ernst E</AU>
<TI>Valerian for insomnia: a systematic review of randomized clinical trials</TI>
<SO>Sleep Medicine</SO>
<YR>2000</YR>
<VL>1</VL>
<NO>2</NO>
<PG>91-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-1978" NAME="Taylor 1978" TYPE="BOOK">
<AU>Taylor CB</AU>
<SO>Relaxation training and related techniques in behavioural modifications: Principles and clinical applications</SO>
<YR>1978</YR>
<ED>Agras WS</ED>
<PB>Little Brown</PB>
<CY>Boston, MA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-1988" NAME="Taylor 1988" TYPE="BOOK">
<AU>Taylor CB, Arnow B</AU>
<SO>The nature and the treatment of anxiety disorders</SO>
<YR>1988</YR>
<PB>Free Press</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-Eickstedt-1969" NAME="Von Eickstedt 1969" TYPE="JOURNAL_ARTICLE">
<AU>Von Eickstedt KW, Rahman S</AU>
<TI>Psychopharmacologic effect of valepotriates</TI>
<TO>Psychopharmakologische wirkungen von valepotriaten</TO>
<SO>Arzneimittel-Forschung</SO>
<YR>1969</YR>
<VL>19</VL>
<NO>3</NO>
<PG>316-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vorbach-1996" NAME="Vorbach 1996" TYPE="JOURNAL_ARTICLE">
<AU>Vorbach EU, Gortelmeyer R, Bruning J</AU>
<TI>Therapy of insomnia. The efficacy and tolerability of valerian</TI>
<TO>Therapie von Insomnien. Wirksamkeit und Vertraglichkeit eines Baldrianpraparats</TO>
<SO>Psychopharmakotherapie</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>3</NO>
<PG>109-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walley-1994" NAME="Walley 1994" TYPE="JOURNAL_ARTICLE">
<AU>Walley EJ, Beebe DK, Clark JL</AU>
<TI>Management of common anxiety disorders</TI>
<SO>American Family Physician</SO>
<YR>1994</YR>
<VL>50</VL>
<NO>8</NO>
<PG>1745-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ziegler-2002" NAME="Ziegler 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ziegler G, Ploch M, Miettinen-Baumann A, Collet W</AU>
<TI>Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia, a randomized double blind comparative clinical study</TI>
<SO>European Journal of Medical Research</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>11</NO>
<PG>480-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Andreatini-2002">
<CHAR_METHODS>
<P>Allocation: randomised (computer program)<BR/>Blindness: unclear<BR/>Design: parallel<BR/>Duration: 4 weeks<BR/>Analysis: non ITT<BR/>São Paulo, Brazil</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=36<BR/>Diagnosis: GAD (DSM-III-R)<BR/>Gender: 21 females<BR/>Age: mean of 41 years<BR/>Setting: ambulatory<BR/>History: most of patients presented an associated clinical disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Valerian 81,3 mg/day (N=12)</P>
<P>2. Diazepam 6,5 mg/day (N=12)</P>
<P>3. Placebo (N=12)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-A (LOCF)<BR/>STAI (LOCF)<BR/>Side-effects<BR/>Dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>HAM-A - Hamilton Anxiety Scale<BR/>LOCF - Last Observartion Carried Forward<BR/>STAI - State-trait Anxiety Inventory</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bourin-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used a combination of six extracts.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cerny-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised<BR/>Participants: 98 healthy volunteers<BR/>Interventions: (1) Valeriana/lemon balm; (2) placebo ; 30 days<BR/>Outcomes: sleep quality.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Delsignore-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised<BR/>Participants: 40 subjects with minor anxiety symptomatology and emotional tension disturbances<BR/>Interventions: (1) Valeriana 50 mg 3x day; (2) placebo 3x day; 21 days<BR/>Outcomes: clinical outcomes not available for meta-analysis. Continuous data (HAM-A) without SD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maisenbacher-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised<BR/>Participants: 2395 subjects with acute or subacute psychophysical ill-health<BR/>Interventions: (1) Valeriana and Melissa; (2) placebo; 4 weeks<BR/>Outcomes: clinical outcomes not available for meta-analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCutcheon-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised<BR/>Participants: 72 subjects with minor anxiety symptomatology and emotional tension disturbances<BR/>Interventions: (1) Valeriana and other 8 homeophatic remedies; (2) placebo ; 15 days<BR/>Outcomes: . STAI trait and state, Mean, SD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Panijel-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Valerian combined with hypericum for comparison with diazepam.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rabezzana-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Standard deviations were not shown for continuous outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Andreatini-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Valerian vs placebo</NAME>
<CONT_OUTCOME CHI2="0.6506675218537463" CI_END="1.940401303652551" CI_START="-3.134880236312638" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5972394663300433" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.7222863000958045" P_Q="0.7222863000958045" P_Z="0.6445963455825221" Q="0.6506675218537463" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="36" UNITS="" WEIGHT="300.0" Z="0.461281934779459">
<NAME>Reduction in anxiety symptoms (HAM-A)</NAME>
<GROUP_LABEL_1>Valerian</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Valerian</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.1311713335453355" CI_START="-7.931171333545336" DF="0.0" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="1.0" P_Z="0.674389531044177" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="99.99999999999999" Z="0.42013131155549854">
<NAME>total score</NAME>
<CONT_DATA CI_END="5.1311713335453355" CI_START="-7.931171333545336" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="14.6" MEAN_2="16.0" ORDER="709" SD_1="9.8" SD_2="6.1" SE="3.3322915038553678" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.921577708850709" CI_START="-3.121577708850708" DF="0.0" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="0.8238286250567405" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.22262339741805148">
<NAME>somatic factor</NAME>
<CONT_DATA CI_END="3.921577708850709" CI_START="-3.121577708850708" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="4.5" ORDER="710" SD_1="4.3" SD_2="4.5" SE="1.7967563366615222" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.6189835564145065" CI_START="-6.218983556414508" DF="0.0" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" NO="3" P_CHI2="1.0" P_Z="0.4246622118234531" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.798358972630939">
<NAME>psychic factor</NAME>
<CONT_DATA CI_END="2.6189835564145065" CI_START="-6.218983556414508" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="11.5" ORDER="711" SD_1="6.0" SD_2="5.0" SE="2.254624876411447" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.32877704560814" CI_START="-9.928777045608134" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7000000000000028" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8972934354979909" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.1290811523556184">
<NAME>Reduction in anxiety symptoms (STAI-T)</NAME>
<GROUP_LABEL_1>Valerian</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Valerian</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.32877704560814" CI_START="-9.928777045608134" EFFECT_SIZE="0.7000000000000028" ESTIMABLE="YES" MEAN_1="52.7" MEAN_2="52.0" ORDER="712" SD_1="15.3" SD_2="10.9" SE="5.422945079321138" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.450631558527997" CI_START="0.014912978884848133" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.4882790296766242" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6930486441661347">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Valerian</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Valerian</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.450631558527997" CI_START="0.014912978884848133" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.4771212547196625" NO="1" P_CHI2="1.0" P_Z="0.4882790296766242" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6930486441661347">
<NAME>Somnolence</NAME>
<DICH_DATA CI_END="7.450631558527997" CI_START="0.014912978884848133" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="713" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.9846277727482295" CI_START="0.16709476979564683" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.7770371436699752" LOG_CI_START="-0.7770371436699752" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.0">
<NAME>Overall dropout</NAME>
<GROUP_LABEL_1>Valerian</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Valerian</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.984627772748228" CI_START="0.16709476979564689" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7770371436699751" LOG_CI_START="-0.777037143669975" LOG_EFFECT_SIZE="0.0" ORDER="714" O_E="0.0" SE="0.9128709291752768" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" VAR="0.8333333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Valerian vs diazepam</NAME>
<CONT_OUTCOME CHI2="0.1022536709118285" CI_END="2.2559789095968514" CI_START="-2.130276592918958" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.06285115833894647" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.9501581519371463" P_Q="0.9501581519371463" P_Z="0.955207098816819" Q="0.1022536709118285" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="36" UNITS="" WEIGHT="300.0" Z="0.0561690976097056">
<NAME>Reduction in anxiety symptoms (HAM-A)</NAME>
<GROUP_LABEL_1>Valerian</GROUP_LABEL_1>
<GROUP_LABEL_2>Diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Valerian</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursBenzodiazepin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.022435720306486" CI_START="-6.2224357203064855" DF="0.0" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="1.0" P_Z="0.9057639814357245" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.11838326968007772">
<NAME>total score</NAME>
<CONT_DATA CI_END="7.022435720306486" CI_START="-6.2224357203064855" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="14.6" MEAN_2="14.2" ORDER="715" SD_1="9.8" SD_2="6.4" SE="3.3788558221188825" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.5328439747936886" CI_START="-2.932843974793687" DF="0.0" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="1.0" P_Z="0.8859445270955828" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.14343767903456778">
<NAME>somatic factor</NAME>
<CONT_DATA CI_END="2.5328439747936886" CI_START="-2.932843974793687" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="5.1" ORDER="716" SD_1="4.3" SD_2="2.2" SE="1.3943337716151993" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.018983556414507" CI_START="-3.8189835564145076" DF="0.0" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" NO="3" P_CHI2="1.0" P_Z="0.7901470564603281" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.2661196575436461">
<NAME>psychic factor</NAME>
<CONT_DATA CI_END="5.018983556414507" CI_START="-3.8189835564145076" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="9.1" ORDER="717" SD_1="6.0" SD_2="5.0" SE="2.254624876411447" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="20.896222713047266" CI_START="1.9037772869527476" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.400000000000006" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.018628027942929202" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="2.3528923129675374">
<NAME>Reduction in anxiety symptoms (STAI-T)</NAME>
<GROUP_LABEL_1>Valerian</GROUP_LABEL_1>
<GROUP_LABEL_2>Diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Valerian</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Benzodiazepi</GRAPH_LABEL_2>
<CONT_DATA CI_END="20.896222713047266" CI_START="1.9037772869527476" EFFECT_SIZE="11.400000000000006" ESTIMABLE="YES" MEAN_1="52.7" MEAN_2="41.3" ORDER="718" SD_1="15.3" SD_2="6.9" SE="4.845100618150258" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.450631558527997" CI_START="0.014912978884848133" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.4882790296766242" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.6930486441661347">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Valerian</GROUP_LABEL_1>
<GROUP_LABEL_2>Diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Valerian</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Benzodiazepi</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.450631558527997" CI_START="0.014912978884848133" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="719" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.9846277727482295" CI_START="0.16709476979564683" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.7770371436699752" LOG_CI_START="-0.7770371436699752" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.0">
<NAME>Overall dropout</NAME>
<GROUP_LABEL_1>Valerian</GROUP_LABEL_1>
<GROUP_LABEL_2>Diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Valerian</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Benzodiazepi</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.984627772748228" CI_START="0.16709476979564689" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7770371436699751" LOG_CI_START="-0.777037143669975" LOG_EFFECT_SIZE="0.0" ORDER="720" O_E="0.0" SE="0.9128709291752768" STUDY_ID="STD-Andreatini-2002" TOTAL_1="12" TOTAL_2="12" VAR="0.8333333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>